Summary: The IDSA guidelines recommend the use of granulocyte colony-stimulating factor (G-CSF) in patients with a greater than 20% likelihood of profound neutropenia. Cost-effectiveness studies have shown that G-CSF reduces the incidence of complications in patients at risk of profound neutropenia and is beneficial as a prophylactic treatment in patients with prior episodes of febrile neutropenia associated with infection.